Rhythm Pharmaceuticals

Rare Genetic Disorders of Obesity

Our lead product candidate, setmelanotide, is an investigational, first-in-class MC4R agonist undergoing clinical trials for the treatment of rare genetic disorders of obesity.

LEARN ABOUT OUR PRODUCT PIPELINE ▸

INFORMATION AND RESOURCES

For Patients & Caregivers ▸

Listen, Empower, Advocate, and Drive Change
for rare genetic disorders of obesity

For Healthcare Providers ▸

Not All Obesity is the Same